Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Agreed, being out of the stock lets one see more clearly. In hindsight, feeling pretty foolish for holding out as long as I did. Poor management aside, the overriding reason the company is valued at sub-$50 million is because the data has not been good enough to attract and sustain any paying partner who believes the platform has a chance at commercial success. ADXS is late stage so it is the clinical trial data in aggregate that has led to the collapse of the company's value and institutional investors and partners fleeing and why for the last two years across the three different CEOs ADXS has not been able to find any BP willing to invest in AXAL or HOT and why Amgen decided it was better to loose $65 million already put into NEO rather than the likelihood of loosing more after assessing the prelim NEO trial data.